In summary, our findings demonstrate that IL‐36α expression is associated with poor prognosis in patients with NSCLC, and IL‐36α exerts potent anticancer efficiency in NSCLC involved with, or partly, reducing tumor angiogenesis via inhibiting VEGFA expression. Here, IL36A is linked to non-small cell lung carcinoma.